MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

The MyeloMATCH study is a screening program designed to help doctors find the most effective clinical trials for patients with myeloid cancers, such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Instead of a "one-size-fits-all" approach, this study uses advanced laboratory testing to look for specific biomarkers—genetic markers or molecules—driven by your unique cancer. By identifying these markers, doctors can try to match you with a specialized treatment study that targets your specific type of disease. If a matched trial isn't available, you will receive the current standard of care treatment while remaining in the program for monitoring.

To join this study, you must be at least 18 years old and have a suspected or confirmed diagnosis of AML or MDS that has not been treated before. You generally cannot have received prior chemotherapy, though your doctor can explain specific exceptions for certain medications used to manage blood counts. Participation involves providing blood and bone marrow samples for detailed testing. Depending on which treatment path you are matched to, you may also undergo imaging like CT scans or X-rays. Because this is a screening protocol, you should talk to your doctor about how the test results will guide your treatment options and what to expect if you are matched to a specific clinical trial versus standard therapy.